SanBio Company Limited
4592 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区明石町８番１号
- Website:
- https://www.sanbio.com/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
SanBio Company Limited is a Japanese biotechnology firm focused on advancing regenerative medicine and innovative therapeutic solutions. The company is renowned for its proprietary product, AKUUGO®, designed for intracranial implantation, which aims to improve patient outcomes in neurological care. SanBio's extensive research and development efforts, led by a world-class team, emphasize large-scale production technology and the delivery of effective medical care to a broad patient population. The company actively engages in collaborations and discussions within the biopharma community, reflected in its leadership roles and participation in international seminars. SanBio is committed to pioneering advancements in healthcare through cutting-edge research and regulatory compliance.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-13 08:45 |
Inside Information Statement
臨時報告書
|
Japanese | 19.2 KB | |
| 2025-04-24 08:31 |
Inside Information Statement
臨時報告書
|
Japanese | 23.7 KB | |
| 2025-04-23 08:31 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2025-04-23 08:31 |
Internal Control over Financial Reporting
内部統制報告書－第12期(2024/02/01－2025/01/31)
|
Japanese | 21.6 KB | |
| 2025-04-23 08:30 |
Annual Report
有価証券報告書－第12期(2024/02/01－2025/01/31)
|
Japanese | 1.3 MB | |
| 2025-03-17 07:30 |
Inside Information Statement
臨時報告書
|
Japanese | 21.2 KB | |
| 2025-02-14 07:30 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 168.5 KB | |
| 2024-12-25 07:30 |
Inside Information Statement
臨時報告書
|
Japanese | 19.3 KB | |
| 2024-12-02 07:30 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 112.5 KB | |
| 2024-09-17 08:02 |
Inside Information Statement
臨時報告書
|
Japanese | 19.0 KB | |
| 2024-09-17 08:01 |
Regulatory News Service
確認書
|
Japanese | 7.9 KB | |
| 2024-09-17 08:01 |
Interim Report
半期報告書－第12期(2024/02/01－2024/07/31)
|
Japanese | 181.0 KB | |
| 2024-06-13 08:02 |
Inside Information Statement
臨時報告書
|
Japanese | 19.0 KB | |
| 2024-06-13 08:01 |
Regulatory News Service
確認書
|
Japanese | 7.9 KB | |
| 2024-06-13 08:01 |
Quarterly Report
四半期報告書－第12期第1四半期(2024/02/01－2024/04/30)
|
Japanese | 137.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |